Docket No.: PF-0025-4 DIV

Certificate of Mailing

"Certificate of Express Mail" mailing label number EV 310 863 635 US I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Wail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 28, 2003.

By: f lanex ham

Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Guegler et al.

Title:

CHEMOKINE EXPRESSED IN INFLAMED ADENOID

Serial No.:

To Be Assigned

Filing Date:

Herewith

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No. 09/588,044, filed June 5, 2000, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

115690

Docket No.: PF-0025-4 DIV

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE CORPORATION

Date: October 28, 2003

Terence P. Lo

Limited Recognition (37 C.F.R. 10.9 (b)) attached

Direct Dial Telephone: (650) 621-8581

Customer No.: 27904 3160 Porter Drive

Palo Alto, California 94304 Phone: (650) 855-0555 Fax: (650) 845-4166

115690 2

												
U.S. Department of Commerce, Patent and Trademark Office						Atty Docket No.		Serial No.				
					PF-0025-4 DIV		To Be Assigned					
LIST OF REFERENCES CITED BY APPLICANTS						Applicant						
(Use several sheets if necessary)						Guegler et al.						
						Filing Date		Group				
						Herewith		To Be Assigned				
			U.S.	Patent Documents								
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing I If Appro					
	1	5,011,912	4/30/91	Hopp et al.								
	Foreign Patent Documents											
							Translation					
		Document	Date	Country	Class	Subclass	Yes	No				
	ОТН	IER ART (In	cluding Auth	or, Title, Date,	Pertiner	it Pages, El	cc.)					
	2	Vilcek, J. et al., "Immunology of Cytokines <u>The Cytokine Handbook</u> Academic Press, Copyright 1991, Chapter 1, pp. 1-17										
	3	Shaw, A.R., "Molecular Biology of Cytokines" The Cytokine Handbook, Academic Press, Copyright 1991, Chapter 2, pp. 20-46										
	4	Banchereau, J., "Interleukin-4" <u>The Cytokine Handbook</u> , Academic Press, Copyright 1991, Chapter 6, pp. 120-148										
	5	Schall, T.J., "The Chemokines" <u>The Chemokine Handbook</u> , Academic Press, 1994, September 19-20, Second Edition, pp. 180-272										
	6	Uhlmann et al., "Antisense Oligonucleotides: a New Therapeutic Principle" <u>Chemical Reviews</u> 90(4):554-584 (1990)										
	7	Cotten et al., "Ribozyme Mediated Destruction of RNA in vivo" The EMBO Journal 8(12):3861-3866 (1989)										
	80	Ledley, F.D., "Clinical Consideration in the Design of Protocols for Somatic Gene Therapy" <u>Human Gene Therapy</u> 2:77-82 (1991)										
	9	Anderson, W.F., "Prospects for Human Gene Therapy" <u>Science</u> 226:401-409 (1984)										
	10	Opdenakker et al., "The Human MCP-3 Gene (SCYA7): Cloning, Sequence Analysis, and Assignment to the C-C Chemokine Gene Cluster on Chromosome 17q11.2-q12" Genomics 21:403-408 (1994)										
	11	Diamond et al., "Novel delayed-early and highly insulin-induced growth response genes. Identification of HRS, a potential regulator of alternative pre-mRNA splicing" <u>Journal of Biol. Chem.</u> 268(20):15185-15192 (1993)										
	12 Derynck et al., (1990) Biochemistry Vol. 29, pp. 10225-10233.											
Examiner			Date Consid	dered								
			<u> </u>				 					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

13	Bork et al., Trends in Genetics, Vol. 12, No. 10, pp. 425-427 (1996)
14	Doerks et al., Trends in Genetics, Vol. 14, No. 6, pp. 248-250 (1998)
 15	Brenner et al., Trends in Genetics, Vol 15, No. 8, pp. 132-133 (1999)
16	Schall, T. et al., "Chemokines, leukocyte trafficking, and inflammation", Current Opinion in Immunology 1994, 6:865-873

		·
Examiner	Date Considered	•

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.